The experimental vaccine candidate, developed by researchers at the University of Southern California in Los Angeles, aims to fight superbug infections like methicillin-resistant Staphylococcus aureus, which can easily spread via surfaces.
Rather than activating antibodies, the experimental vaccine works by activating immune cells known as macrophages, which kill off bacteria and neutralize any bodily invaders, according to the Oct. 4 USC news release.
“This is very different from developing new antibiotics,” Jun Yan, lead study author and doctoral candidate at the USC Keck School of Medicine stated in the release. “This is using our own immune system to fight against different superbugs, which is a different approach than everybody else.”
In lab tests, the experimental vaccine was effective after 24 hours for a duration of about 28 days.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
